First-Line Treatment for Newly Diagnosed Asthma in Adults

Initial Treatment Strategy

The American Academy of Family Physicians recommends initiating low-dose inhaled corticosteroid (ICS) as the preferred first-line controller therapy, with an as-needed short-acting beta-agonist (SABA) for symptom relief in adults newly diagnosed with asthma 1, 2
For intermittent asthma, the preferred treatment is a short-acting beta-agonist (albuterol/salbutamol) as needed only, applicable if symptoms occur ≤2 days per week, nighttime awakenings ≤2 times per month, and no interference with normal activities 1, 2
For mild persistent asthma, the preferred treatment is a low-dose inhaled corticosteroid (fluticasone 100-250 mcg daily or equivalent), with alternative options including cromolyn, leukotriene receptor antagonist, nedocromil, or theophylline, although these are less effective 1, 2
As-needed SABA should be used for acute symptom relief in mild persistent asthma 1

The American Academy of Family Physicians recommends determining asthma severity by evaluating daytime symptoms, nighttime awakenings, SABA use for symptom relief, interference with normal activities, and objective lung function, such as FEV1 or PEF measurement 1, 2, 3
SABA use more than twice weekly indicates a need for controller therapy 1, 3

Patient education should include a written asthma action plan with green, yellow, and red zone instructions, proper inhaler technique, and explanation of the difference between controller and reliever medications 2, 3
Environmental control measures and trigger avoidance should be instructed 1, 2
Follow-up visits should be scheduled every 2-6 weeks initially to assess response to therapy, and once control is achieved, intervals can be extended to every 1-6 months 3
Monitoring for SABA overuse (>2 days per week) is crucial, as it suggests inadequate control and the need to step up therapy 1, 3

If symptoms persist despite low-dose ICS after 4-6 weeks, the preferred approach is to add a long-acting beta-agonist (LABA) to low-dose ICS, or increase to medium-dose ICS monotherapy 1, 2

For adult-onset asthma, consider occupational exposures as potential triggers, assess for comorbidities such as GERD, rhinosinusitis, and obstructive sleep apnea, and consider subcutaneous allergen immunotherapy as adjunctive therapy if allergic triggers are identified 1, 2